Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.

Keywords

Gemfibrozil, Fibrate, Fenofibrate, Statin, Dyslipidemia

References

• Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrateCarl Kyrklund, Janne T. Backman, Kari T. Kivistö — 2001
• Rhode Island physicians' recognition and reporting of adverse drug reactions.Scott Hd, Rosenbaum Se, Waters Wj — 1987
• CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.Tanja Busk Bidstrup, Inga Bjørnsdottir, Ulla G. Sidelmann — 2003
• Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinideMikko Niemi, Janne T. Backman, Mikko Neuvonen — 2003
• Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.Baldwin, Clarke, Chenery — 2001
• Effects of fibrates on metabolism of statins in human hepatocytes.Thomayant Prueksaritanont, Cuyue Tang, Yue Qiu — 2002
• The effect of gemfibrozil on the pharmacokinetics of rosuvastatinDennis W. Schneck — 2004
• Lack of a Clinically Significant Pharmacokinetic Interaction between Fenofibrate and Pravastatin in Healthy VolunteersWei‐Jian Pan, Linda E. Gustavson, Ramanuj Achari — 2000
• The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day.Michael Davidson, Evan A. Stein, Carlos A. Dujovne — 1997
• Gemfibrozil considerably increases the plasma concentrations of rosiglitazoneMikko Niemi, Janne T. Backman, Marika T. Granfors — 2003
• Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearanceCarl Kyrklund — 2003
• Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemiaMichael H. Davidson — 2002
• Mechanistic studies on metabolic interactions between gemfibrozil and statins.Thomayant Prueksaritanont, Jamie J. Zhao, Bennett Ma — 2002
• Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.Junsheng Wang, Mikko Neuvonen, Xia Wen — 2002
• Combination therapy for dyslipidemia: safety and regulatory considerations.Michael H. Davidson — 2002
• Gemfibrozil greatly increases plasma concentrations of cerivastatinJanne T. Backman — 2002
• Cerivastatin and reports of fatal rhabdomyolysis.Judy A. Staffa, Jennie Chang, Lanh Green — 2002

Cited by

• Overcoming ‘Ageism’ Bias in the Treatment of HypercholesterolaemiaTerry A. Jacobson — 2006
• Reducing residual risk for patients on statin therapy: the potential role of combination therapy.María Gómez Rodrigo — 2005
• Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological studyAndrew S. West — 2006
• Fibrates: What Have We Learned in the Past 40 Years?Тараборин Роман Сергеевич — 2007
• Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reductionEmilio Mitre Fernández — 2012
• Awareness, knowledge and practice of dyslipidaemia management among postgraduate primary care trainees in Malaysia: a cross-sectional studySara K. Thompson, Rosemary Gartner — 2017
• Intestinal and hepatic drug transporters and their role in the disposition of lipid-lowering drugsUte I. Schwarz — 2012
• Remodelage de la paroi artérielle : étude des aspects de destruction et de reconstructionFabrice Schneider — 2011
• A New Perspective in the Treatment of DyslipidemiaGeorge Steiner — 2005
• Drug Induced Muscle DisordersJohn Smithson — 2009
• National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management--2005.Andrew Tonkin, Philip J. Barter, James D. Best — 2005
• Drug Class Review on HMG-CoA Reductase Inhibitors (Statins): Final ReportMark Helfand, Shannon S. Carson, Catherine L. Kelley — 2006
• Hyperlipidemia management for primary care : an evidence-based approachBrian V Reamy — 2008
• Interplay between proteins and metabolic syndrome–A reviewNeetu Miglani, Kiran Bains — 2017
• Determinants of cholesterol goal attainment at 12 months in patients with hypercholesterolaemia not at consensus goal after 3 months of treatment with lipid‐lowering drugsPeter Lindgren, Fredrik Borgström, Jan Stålhammar — 2007
• Treating dyslipidaemia in the setting of diabetes mellitus and cardiovascular disease: a less commonly perceived therapeutic perspective in clinical practiceGeorge Varughese, J. H. B. Scarpello — 2006
• Pharmacotherapy of Mixed Hyperlipidemia with Ezetimibe–Fenofibrate Combination TherapyMichel Farnier — 2009
• Puesta al día en el manejo de las dislipidemiasKunstmann F. Sonia, De Grazia K. Renata — 2012
• Tratamiento de las hiperlipidemias. Estilos de vida: factores dietéticos y actividad física. Medicación. Grupos farmacológicos: clasificación, indicaciones, contraindicaciones, posología, efectos secundarios e interacciones farmacológicasL.A. lvarez-Sala Walther, Ana Torres do Rego, A. del Castillo Rueda — 2008
• Lipidstoffwechsel aktuell: statininduzierte MyopathienLino L. Teichmann, Martin Fleck — 2010

Related papers

• Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use.Noa Holoshitz, Alawi Alsheikh‐Ali, Richard H. Karas — 2008
• Effect of Three Fibrate Derivatives and of Two HMG-CoA Reductase Inhibitors on Plasma Fibrinogen Level in Patients with Primary HypercholesterolemiaAdriana Branchi, A. Rovellini, D. Sommariva — 1993
• [Fatal rhabdomyolysis caused by cerivastatin].André Scheen — 2001
• Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles.H. Wilmink — 2001
• Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactionsMichael H Davidson — 2006
• [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].Mitsuo Saito, Mutsuko Hirata‐Koizumi, Shinji Miyake — 2005
• Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction.Amy Kind, Laura Zakowski, Patrick E. McBride — 2002
• Risk of adverse events with fibrates.Alawi Alsheikh‐Ali, Jeffrey T. Kuvin, Richard H. Karas — 2004
• Statin-fibrate combination therapy.William E. Feeman — 2008
• Combination of atorvastatin and gemfibrozil plus physical activity: an animal model of statin/fibrate-induced myopathyMohsen Zabihi, Mohsen Zabihi, Fatemeh Askarian — 2020